Table 2.
Subjects with post-treatment medical therapy, randomized cohort
| Subj # | Preop unmedicated IOP (mmHg) | Postop exam when med was addeda | IOP (mmHg) at exam when med was added | Medication added |
|---|---|---|---|---|
| 2-Stent group (N = 54) | ||||
| 37 | 30 | Month 1 | 30 | Brimonidine, timolol |
| 61 | 25 | Month 1 | 26 | Tafluprost |
| 72 | 26 | Month 3 | 23 | Travoprost, timolol |
| 7 | 24 | Month 18 | 16b | Tafluprost |
| 82 | 25 | Month 18 | 18b | Timolol |
| 34 | 28 | Month 36 | 19b | Timolol |
| Travoprost group (N = 47) | ||||
| 56 | 38 | Month 1 | 26 | Brinzolamide, timolol |
| 62 | 32 | Month 1 | 28 | Brinzolamide |
| 93 | 29 | Month 1 | 23 | Brinzolamide |
| 81 | 38 | Month 3 | 32 | Brinzolamide |
| 97 | 30 | Month 3 | 25 | Brinzolamide, timolol |
| 41 | 21 | Month 24 | 20b | Timolol |
| 76 | 26 | Month 24 | 18b | Timolol |
| 4 | 23 | Month 30 | 19b | Betoptic |
| 65 | 29 | Month 30 | 18b | Betoptic |
| 10 | 22 | Month 36 | 19b | Timolol |
| 14 | 22 | Month 36 | 19b | Timolol |
IOP intraocular pressure
aDoes not reflect all study visits following treatment. The complete schedule of postoperative visits for both groups was as follows: day 1, week 1, and at months 1, 3, 6, 12, 18, 24, 30, 36, 42, 48, 54 and 60
bMedication added due to optic nerve findings